Abuhelwa et al reported a score for predicting hand-foot syndrome in a patient treated with sorafenib. The authors are from Flinders University in Australia and Prince of Sonkla University in Thailand.
Patient selection: sorafenib therapy in a patient with hepatocellular carcinoma
Outcome: risk of Grade 3, 4 or 5 hand-foot syndorme
Parameters:
(1) sex of the patient
(2) hemoglobin in g/L
(3) serum total bilirubin in µmol/L
Parameter
Finding
Points
sex of the patient
male
0
female
1
hemoglobin
< 130 g/L
0
>= 130 g/L
1
bilirubin
>= 20 µmol/L
0
10 to 19.99 µmol/L
1
< 10 µmol/L
2
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the greater the risk of Grade >= 3 hand-foot syndrome.
Score
Risk
56-Day Risk
365-Day Risk
0 or 1
low
12%
14%
2
intermediate
22%
27%
3 to 5
high
35%
40%
To read more or access our algorithms and calculators, please log in or register.
